Jul 14, 2026 | Press Releases
Strategic execution across multiple initiatives positions the Entolimod platform to pursue opportunities in government preparedness, domestic biomanufacturing and oncology supportive careSAN ANTONIO, July 14, 2026 /PRNewswire/ — Valion Bio, Inc. (Nasdaq: VBIO)...
Jun 25, 2026 | Press Releases
AFRRI/NIAID partnership and validated animal models significantly derisk regulatory and commercial advancement of Company’s lead candidatePositive momentum further positions Entolimod as a potential first and only treatment for GI-ARS, representing a...
Jun 11, 2026 | Press Releases
Emanates from the FY27 NDAA process underway in the U.S. CongressPrioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) Follows Company’s two recent briefings for senior DoW officials regarding...
May 19, 2026 | Press Releases
Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical CountermeasureSAN ANTONIO, May 19, 2026 /PRNewswire/ — Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented...
May 14, 2026 | Press Releases
First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Generation NMR-Based DiagnosticsSAN ANTONIO, May 14, 2026 /PRNewswire/ — Valion Bio, Inc. (formerly Tivic Health...